Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vector-free delivery of gene editing proteins and compositions to cells and tissues

A technology of gene editing and composition, applied in vectors, nucleic acid vectors, gene therapy, etc., can solve the problems of difficult detection of previous events, expensive regulatory procedures, and problems, and achieve good gene editing efficiency, less off-target effects, and survival good vitality effect

Active Publication Date: 2019-02-05
AVECTAS
View PDF12 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While the latter event can at least be predicted and monitored, the former event can be difficult to detect and thus may be more problematic
Regardless of the site of integration, these foreign sequences elicit host immune responses, presenting challenges for the use of gene-edited stem or primary cells in clinical applications
Furthermore, plasmid-transfected cells intended for clinical applications are considered genetically modified by regulatory authorities and are therefore subject to lengthy and costly regulatory procedures

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vector-free delivery of gene editing proteins and compositions to cells and tissues
  • Vector-free delivery of gene editing proteins and compositions to cells and tissues
  • Vector-free delivery of gene editing proteins and compositions to cells and tissues

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0207] Example 1: The data described herein were generated using the following materials and methods.

[0208] Cells and Cell Culture

[0209] A549 cells (A549 European Cell Culture Collection (ECACC) cells were purchased through Sigma-Aldrich Company (category number 86012804) (St.Louis, MO, USA) and Beas-2B (Sigma-Aldrich Company, catalog number 95102433), and Routine culture in DMEM (Gibco) supplemented with 5% fetal calf serum and 2mM L-glutamine (Gibco). Jurkat cells (European Collection of Cell Cultures; ECACC) were incubated at 37°C, 5% CO 2 were grown and maintained in RPMI 1640 (Gibco) supplemented with 10% (v / v) FBS (Sigma) and 1% (v / v) penicillin / streptomycin. Primary human PBMCs were freshly isolated and cultured in supplemented with 10% (v / v) heat-inactivated FBS, 0.01% (v / v) 2-β-mercaptoethanol (Life Sciences) and 1% (v / v) L- Glutamine in RPMI 1640 (Gibco) at 37°C, 5% CO 2 down to maintain. CD34+ bone marrow-derived cells (HSCs) were purchased from Lonza,...

Embodiment 2

[0270] Example 2: Establishing and testing the function of the gene editing tool and the impact of the delivery solution on the function of the gene editing tool In vitro editing analysis of

[0271] The Crispr Cas9 system for gene editing has been widely adopted. However, most users use the DNA plasmid form of Cas9 in conjunction with guide RNA. Systems that deliver forms of RNP are of interest as this is more transient and should therefore lead to fewer off-target effects. The necessary tools (recombinant Cas9 nuclease, single guide, two-part guide) have recently become commercially available. Custom guide RNA sequences were designed based on corresponding plasmid sequences reported in the literature. Perform a confirmatory analysis to check the quality of the reagents. To evaluate gene editing tools, an assay for in vitro editing tests based on the Agilent SureGuide Cas9 Programmable Nuclease Kit was developed. In this assay, Cas9 protein is incubated with a guide (...

Embodiment 3

[0293] Example 3: Conjugation of Cas9 to a fluorescent label for visualization of delivery into cells.

[0294] To utilize the delivery platform technology to analyze whether Cas9 enters the cell after delivery, conjugation of the protein with a fluorescent label was explored. Cas9 labeling methods targeting amine groups must be avoided as they lead to Cas9 precipitation due to the physicochemical properties of Cas9. Therefore, Cas9 was labeled with the fluorescent tag Alexa-488 maleimide via the sulfhydryl group of cysteine ​​(2 cysteine ​​residues per molecule of protein). This reaction did not alter the overall charge of the protein at physiological pH. The experimental protocol followed was based on previous work (Zuris, JA et al., Nat Biotechnol 2015; 33(1) 73-80).

[0295] Material

[0296] Cas9 was purchased from Toolgen Genome Engineering (Korea) or IDT Integrated DNA Technologies (USA). TCEP (tris(2-carboxyethyl)phosphine), Hepes, glycerol and KCl were of anal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present subject matter provides a method for delivering a gene editing composition across a plasma membrane of a cell. Related apparatus, systems, techniques, compositions, and articles are also described.

Description

[0001] related application [0002] This application claims priority to US Provisional Application No. 62 / 273,284, filed December 30, 2015, the entire contents of which are incorporated herein by reference. technical field [0003] The subject matter described herein relates to the carrier-free delivery of gene editing compounds and complexes to cells and tissues. [0004] The sequence listing is incorporated by reference [0005] The content of the 64.2KB text file "48831_506001WO_ST25.txt" created on December 22, 2016 is incorporated herein by reference in its entirety. Background of the invention [0006] Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas genome engineering system (hereinafter referred to as "CRISPR-Cas system") enables researchers to modify genomic DNA inside cells. This system requires three components: Cas9, probably derived from Streptococcus pyogenes, is an endonuclease that complexes with CRISPR RNA (crRNA) and transcription-ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/22C12N15/10C12N15/113
CPCC12N9/22C12N15/113C12N2320/32C12N2310/20C12N15/87B01L3/527B01L3/567B01L5/00B01L2400/0487B01L2400/06C12N15/11C12N2800/80
Inventor M·马奎尔S·奥戴
Owner AVECTAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com